Human CapG Antibody
R&D Systems, part of Bio-Techne | Catalog # AF7177
Key Product Details
Species Reactivity
Human
Applications
Immunocytochemistry, Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Sheep IgG
Product Specifications
Immunogen
E. coli-derived recombinant human CapG
Met1-Lys348
Accession # P40121
Met1-Lys348
Accession # P40121
Specificity
Detects human CapG in direct ELISAs and Western blots.
Clonality
Polyclonal
Host
Sheep
Isotype
IgG
Scientific Data Images for Human CapG Antibody
Detection of Human CapG by Western Blot.
Western blot shows lysates of HeLa human cervical epithelial carcinoma cell line, MOLT-4 human acute lymphoblastic leukemia cell line, and human kidney tissue. PVDF membrane was probed with 0.2 µg/mL of Sheep Anti-Human CapG Antigen Affinity-purified Polyclonal Antibody (Catalog # AF7177) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). A specific band was detected for CapG at approximately 41 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.
CapG in U937 Human Cell Line.
CapG was detected in immersion fixed U937 human histiocytic lymphoma cell line using Sheep Anti-Human CapG Antigen Affinity-purified Polyclonal Antibody (Catalog # AF7177) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Sheep IgG Secondary Antibody (red; Catalog # NL010) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Non-adherent Cells.Applications for Human CapG Antibody
Application
Recommended Usage
Immunocytochemistry
5-15 µg/mL
Sample: Immersion fixed U937 human histiocytic lymphoma cell line
Sample: Immersion fixed U937 human histiocytic lymphoma cell line
Western Blot
0.2 µg/mL
Sample: HeLa human cervical epithelial carcinoma cell line, MOLT‑4 human acute lymphoblastic leukemia cell line, and human kidney tissue
Sample: HeLa human cervical epithelial carcinoma cell line, MOLT‑4 human acute lymphoblastic leukemia cell line, and human kidney tissue
Formulation, Preparation, and Storage
Purification
Antigen Affinity-purified
Reconstitution
Sterile PBS to a final concentration of 0.2 mg/mL. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: CapG
CapG ("Caps" barbed actin ends and resembles Gelsolin; also Macrophage capping protein/MCP and actin regulatory protein Cap-G) is a 40-42 kDa member of the Villin/Gelsolin family of proteins. It is expressed by macrophages/monocytes and endothelial cells, and is found in both cytoplasm and nucleus. It appears to be involved in cell motility, and is known to bind to (but not cleave) actin filament ends in a calcium-dependent manner. This regulates the growth of actin filaments. Human CapG is 348 amino acids (aa) in length. It contains an N-terminal gelsolin repeat (aa 27-75), followed by a NLS (aa 137-146), two consecutive gelsolin-like repeats (aa 148-188 and 261-307), and one utilized phosphorylation site at Ser337. There is at least one potential isoform variant that contains a deletion of aa 64-84. Full-length human CapG shares 91% aa sequence identity with mouse CapG.
Long Name
Capping Protein, Gelsolin-like
Alternate Names
AFCP
Gene Symbol
CAPG
UniProt
Additional CapG Products
Product Documents for Human CapG Antibody
Product Specific Notices for Human CapG Antibody
For research use only
Loading...
Loading...
Loading...
Loading...